Collapsing FSGS Progression to ESRD After Combination Therapy with Pembrolizumab and Enfortumab Vedotin: A Case Report (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0687; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 76-year-old male with high-grade urothelial carcinoma and baseline Stage 4 CKD (eGFR 25 mL/min/1.73 m^2, creatinine 2.5 mg/dL) secondary to prior cisplatin exposure was initiated on PB 200 mg IV and EV 1 mg/kg IV on a 21-day cycle...Both agents were discontinued and rituximab was initiated; however, renal function still deteriorated...Third, once advanced interstitial fibrosis is established, immunosuppressive salvage is unlikely to alter the trajectory, and its toxicity must be weighed against a negligible probability of benefit. Notably, PB-induced cFSGS typically remits within 2–3 months of drug discontinuation; however, the literature on dual therapy with EV remains limited."
Case report • Clinical • Combination therapy • Chronic Kidney Disease • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Immunology • Nephrology • Renal Disease • Solid Tumor • Urothelial Cancer • NECTIN4
|
|
George Hitti; Caroline A. Gee; Ramy Magdy Hanna
|